ANTAGONIST of Interleukin-2 receptor alpha chain antagonist
Product Description
Inolimomab (anti-IL2RA) is an anti-interleukin-2 receptor (IL-2R) α chain monoclonal antibody. Inolimomab (anti-IL2RA) improves the survival rate in the early research of treating acute graft-versus-host disease (aGVHD). Purity ≥95% (SDS-PAGE&SEC) Endotoxin Level < 1.0EU/mg
Product Properties
Isotype
Human IgG1
Light Chain Type
kappa
SDS-PAGE
145.34 kDa
Purification Method
Protein A purified
Form
Liquid
Concentration
Lot by Lot
Storage Temp
Store at -80°C,Avoid repeated freezing and thawing
Shipped In
Ice chest + Ice pads
Stability And Storage
Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS
152981-31-2
Images
Inolimomab (anti-IL2RA) (Ab183060) - Flow Cytometry Flow Cytometry analysis of unstimulated (left) or 500 ng/mL Ionomycin (I139530) and 10 ng/mL PMA (P408905) co-stimulated (right) Jurkat cells labelling IL2RA (red) with Inolimomab (anti-IL2RA) (Ab183060) at 0.1 μg/mL for 1 hour at 4°C. Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Inolimomab (anti-IL2RA) (Ab183060) - ELISA Immobilized Recombinant Human CD25/IL-2R alpha Protein (rp169618) at 1.0 μg/mL can bind Inolimomab (anti-IL2RA) (Ab183060) with the EC
₅₀
of 4.70 ng/mL.
Inolimomab (anti-IL2RA) (Ab183060) - SEC The purity of Inolimomab (anti-IL2RA) (Ab183060) is more than 95% verified by HPLC.